Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Posters

36P - Plasma levels of hsa_circ_0001445 and hsa_circ_0007915 may indicate the presence of metastatic disease in patients with colorectal cancer

Date

06 Oct 2021

Session

e-Posters

Presenters

Maria Radanova

Citation

Annals of Oncology (2021) 32 (suppl_6): S1345-S1371. 10.1016/annonc/annonc740

Authors

M. Radanova1, G. Mihaylova2, O. Tasinov2, D. Ivanova2, N. Nazifova-Tasinova2, R. Manev2, A. Salim2, M. Nikolova2, D. Ivanova2, N. Conev2, Z. Mihaylova3, I. Donev4

Author affiliations

  • 1 Medical University of Varna, Varna/BG
  • 2 Medical University of Varna, 9000 - Varna/BG
  • 3 Military Medical Academy, Sofia Bulgaria, 1000 - Sofia/BG
  • 4 Hospital Nadezhda, Sofia, Bulgaria, 1000 - Sofia/BG
More

Abstract 36P

Background

Circular RNAs (circRNAs) are group of special endogenous long non-coding RNAs (ncRNAs). Their circular form makes them resistant to exonuclease activity compared to linear ncRNAs and thus more suitable as new biomarkers. The aim of our study was to evaluate the expressions of two circRNAs – hsa_circ_0001445 and hsa_circ_0007915 in patients with colorectal cancer (CRC) in different stages of disease in comparison with healthy volunteers (HV).

Methods

122 patients with metastatic CRC (mCRC), 29 adjuvant patients with stage III disease who had undergone radical surgery and postoperative chemotherapy and 90 HV were investigated. All adjuvant patients had normal levels of CEA and they were followed-up regularly for 1 year after the end of their treatment and had no signs of radiological or biochemical relapse. CicrRNAs were extracted from patients’ plasma obtained prior to chemotherapy using a commercial kit. The circRNAs expression levels in plasma samples were measured by qPCR and the relative expression was calculated applying 2-ΔΔCt method.

Results

Patients with mCRC had significantly higher expression of hsa_circ_0001445 and hsa_circ_0007915 than adjuvant patients and HV. At the optimal cut-off values for their plasma levels, hsa_circ_0001445 and hsa_circ_0007915 could significantly distinguish between patients with or without metastatic disease with 92.56% sensitivity and 42.86% specificity and with 86.07% sensitivity and 57.14% specificity (AUC=0.729, 95% CI: 0.62-0.84, p=0.0002; AUC=0.714, 95% CI: 0.59-0.84, p=0.0004), respectively. The mean overall survival (OS) of patients with high/intermediate expression of hsa_circ_0001445 was 30 months (95% CI: 24.99-34.73) in comparison with the mean OS of the patients with low expression – 20 months (95% CI: 16.70-23.76) (log-rank test, p=0.034). In multivariate Cox regression analysis the low levels of hsa_circ_0001445 were also associated with shorter survival (HR=1.59, 95% CI: 1.02-2.47, p=0.040).

Conclusions

Our results indicate that hsa_circ_0001445 in plasma has prognostic significance and the two circRNAs may be useful to differentiate metastatic from non-metastatic CRC patients.

Legal entity responsible for the study

The authors.

Funding

Bulgarian National Science Fund (grant number KII-06-H23/6, 18.12.2018).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.